sar425899 sanofi glp-1 glucagon dual agonist Current GLP-1, GIP, and receptor co-agonists in development Role of a Dual Glucose-Dependent

Unlike the other antidiabetic treatment options, incretin mimetics do not induce hypoglycemia and either cause weight loss or or no change in weight

In India, the drug can be prescribed only by endocrinologists, internal medicine specialists and cardiologists

These treatments are very appealing to individuals with type 2 diabetes and obesity since clinical results show much better weight loss and improved glycemic control

An exciting trend soon emerged

Although not thought to be directly influenced by obesity, lipoprotein (a) is an independent risk factor for cardiovascular disease that is determined by genetics

Should a GLP-1 (Glucagon-like peptide-1) receptor agonist, such as semaglutide (generic name) or tirzepatide (generic name), be continued or discontinued in a patient who has achieved a BMI reduction from 30 to 22?